Track Cogent Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cogent Biosciences, Inc. COGT · Stock Open Cogent Biosciences, Inc. in new tab

28.56 USD
EPS
-2.26
P/B
11.01
ROE
-99.59
Beta
0.34
Target Price
55.82 USD
Loading chart...
Key Metrics
Earnings dateFeb. 16, 2027
EPS-2.26
Book Value2.59
Price to Book11.01
Debt/Equity47.31
% Insiders1.376%
Estimates
Forward P/E-22.08
Forward EPS-1.29
Target Mean Price55.82

DCF valuation

Model fair value for Cogent Biosciences, Inc. (COGT)
Result
Sign in to run the valuation for COGT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 55.82 USD (low 45.00, high 61.00) · as of 15 Nov 2026
Low 45.00
Mean 55.82
High 61.00
Price 28.56
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cogent Biosciences, Inc. Logo Cogent Biosciences, Inc. Analysis (COGT)

United States Health Care Official Website Stock

Is Cogent Biosciences, Inc. a good investment? Cogent Biosciences, Inc. (COGT) is currently trading at 28.56 USD. Market analysts have a consensus price target of 55.82 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cogent Biosciences, Inc. is expected to release its next earnings report on Feb. 16, 2027. The market consensus estimate for Forward EPS is -1.29.

Investor FAQ

Does Cogent Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cogent Biosciences, Inc.?

Cogent Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 16, 2027. The company currently has a trailing EPS of -2.26.

Company Profile

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) COGT
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 9, 2020 1:4
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion